Why Medical Inertia Keeps Outdated and Risky Drugs in the Medicine Cabinets of Older Americans
The lifecycle of a medical guideline revision often follows a frustratingly predictable trajectory in modern healthcare. Clinical researchers identify a widely prescribed pharmaceutical agent, study its long-term effects on aging populations, and publish findings demonstrating that the drug is either significantly less effective than previously understood or that its inherent risks increasingly outweigh its benefits for older adults. Subsequent studies corroborate these outcomes, prompting respected medical associations to update their clinical guidelines. These groups may formally advise that the drug be avoided entirely or prescribed with much greater selectivity. Regulatory agencies, such as the U.S. Food and Drug Administration, might step in with black-box warnings highlighting severe or life-threatening side effects, while influential panels like the Beers Criteria—managed by the American Geriatrics Society—add the substance to their comprehensive lists of potentially inappropriate medications for geriatric patients.
Yet, when researchers analyze broad national health datasets years later to determine whether prescription rates have decreased in response to these warnings, the results are frequently disheartening. While some decline is typically observed, it is rarely enough to match the urgency of the scientific warnings. In many cases, prescription rates remain stubbornly flat, and for certain demographics, usage has actually increased. Experts in geriatric medicine describe this phenomenon using a vivid metaphor: medications act like barnacles on a ship’s hull. They are remarkably easy to initiate, often brought on by a momentary medical need, but they prove exceptionally difficult to remove.
Understanding Medical Inertia and Prescribing Habits
This persistence of outdated prescribing habits is driven by what healthcare professionals refer to as medical inertia. Michael Steinman, a prominent geriatrician at the University of California-San Francisco and co-director of the U.S. Deprescribing Research Network, notes that the problem stems partly from information overload within the medical community. Clinicians must stay abreast of an overwhelming volume of new research across countless specialties, meaning critical safety updates can take years to permeate everyday clinical practice.
Furthermore, medical inertia is deeply rooted in human behavior and clinical routine. Over decades of practice, physicians and patients become accustomed to managing specific health conditions through established pathways. These approaches transform into deeply ingrained habits. Finding alternative, safer non-pharmacological or modern medical approaches requires time, cognitive effort, and specialized knowledge. Consequently, it remains far easier for a busy physician and a comfort-seeking patient to rely on what they already know. Recent in-depth investigations into three widely used medication classes among older Americans—benzodiazepines, antibiotics for uncomplicated conditions, and over-the-counter aspirin for primary prevention—illuminate the severe challenges and public health implications of this phenomenon.
The Persistent Hazards of Benzodiazepines
Scientists first began raising alarms regarding the dangers of benzodiazepines and related sedative-hypnotics more than two decades ago. Prescribed primarily to treat chronic insomnia and generalized anxiety disorders, these medications offer rapid, reliable relief, making them immensely popular among both patients and clinicians. However, this immediate benefit masks a cascade of physiological risks, particularly for older adults whose bodies metabolize drugs more slowly and whose neurological systems are more sensitive to central nervous system depressants.
Pharmacologically, benzodiazepines—which include familiar brand names like Valium, Xanax, and Ativan—alongside related non-benzodiazepine "Z-drugs" such as Ambien and Lunesta, significantly impair balance, neuromuscular coordination, and cognitive processing speed. For aging populations, these impairments frequently translate into catastrophic outcomes, including severe falls, debilitating bone fractures, and dangerous motor vehicle accidents. The risks compound exponentially when patients are simultaneously prescribed opioid analgesics for chronic pain, a combination that drastically elevates the probability of fatal respiratory depression and overdose. Additionally, prolonged use fosters physical and psychological dependence, leading to severe, protracted withdrawal symptoms when attempting cessation.
Recent epidemiological research published in the Annals of Internal Medicine by Dr. Mark Olfson, a psychiatrist and epidemiologist at Columbia University, and his research colleagues highlights both progress and alarming stagnation in prescribing trends. Among adults aged 65 and older, the proportion of patients filling prescriptions for benzodiazepines declined from approximately 14% in 2015 to 11.5% by 2024.
Despite this overall downward trend, the trajectory has stalled significantly since the onset of the COVID-19 pandemic in 2020. Alarmingly, prescribed usage actually ticked upward among the oldest demographic—individuals aged 75 and older—rising from 12% in 2020 to roughly 13% four years later. Even more troubling is the data emerging from long-term care facilities, where the dispensing of these agents through institutional pharmacies more than doubled. Furthermore, approximately one-third of all users maintained their regimens for longer than six months, sharply amplifying their risk of physical dependence. Olfson emphasizes that patients must never attempt to discontinue benzodiazepines abruptly on their own, as sudden cessation can trigger severe withdrawal syndromes. Instead, safe discontinuation requires a carefully managed, medically supervised tapering process that often spans many weeks or months.
Antibiotic Overuse and Diverticulitis
For generations, the standard medical protocol for managing acute diverticulitis—the painful inflammation or infection of small outpouchings, known as diverticula, that form along the walls of the colon—relied heavily on broad-spectrum oral antibiotics. Commonly prescribed agents included fluoroquinolones, such as Ciprofloxacin and Levofloxacin, as well as amoxicillin-clavulanate.
Jesse Sutton, a clinical pharmacist and researcher at the Minneapolis Veterans Affairs healthcare system, describes the historical mindset surrounding these prescriptions as unquestioned dogma. Because antibiotics are universally recognized as lifesaving marvels of modern medicine, the prevailing clinical philosophy was simple: when in doubt, prescribe them.
However, a major paradigm shift occurred in 2015 when the American Gastroenterological Association issued formal clinical guidelines advising against the routine administration of antibiotics for "uncomplicated" diverticulitis, which accounts for the vast majority of all clinical presentations. A succession of other prominent medical organizations quickly followed suit. This policy pivot was driven by robust randomized clinical trials demonstrating that for uncomplicated cases, antibiotic therapy yielded virtually no measurable impact on overall mortality, the necessity for emergency surgery, disease complications, or recurrence rates. In short, the drugs did not improve patient recovery timelines or clinical outcomes.
At the same time, the medical community has grown increasingly vocal about the heavy toll of unintended consequences associated with unnecessary antibiotic exposure. Side effects from these medications account for a substantial percentage of emergency department visits each year, driven by adverse gastrointestinal reactions such as severe nausea, vomiting, and diarrhea. Moreover, unnecessary antibiotic use dramatically heightens a patient’s vulnerability to Clostridioides difficile (C. diff), a virulent, potentially life-threatening intestinal infection that disproportionately impacts older adults. On a macro level, rampant overuse accelerates antimicrobial resistance, a phenomenon the World Health Organization has designated as one of the top ten global public health threats facing humanity.
To measure the real-world adoption of these updated guidelines, Sutton and a team of researchers analyzed treatment patterns across 70,000 patient visits spanning 120 facilities within the Veterans Affairs health system over a ten-year period. Given the clarity of the 2015 guidelines, the researchers anticipated a significant drop in antibiotic utilization. Instead, their findings, published in the Annals of Internal Medicine, revealed that antibiotic prescriptions remained virtually universal, occurring in 97% of outpatient visits for uncomplicated diverticulitis, regardless of official medical guidelines. Patients presenting with this condition would typically have achieved identical recovery outcomes through conservative management involving a few days of acetaminophen and a clear liquid diet.
This systemic overprescribing extends far beyond diverticulitis, frequently manifesting in the treatment of asymptomatic bacteriuria—bacteria in the urine that cause no clinical symptoms, which are often erroneously treated in older adults—and upper respiratory infections that are fundamentally viral rather than bacterial in origin. Sutton advises patients confronted with questionable antibiotic recommendations to gently press their providers for clarity by asking for the specific clinical rationale, reassuring consumers that it is entirely appropriate to pause and seek clarification.
Re-evaluating Aspirin for Primary Prevention
The public health narrative surrounding low-dose aspirin diverges significantly from prescription pharmaceuticals because aspirin is an inexpensive, over-the-counter remedy accessible to anyone without clinical supervision. Consequently, millions of older Americans independently initiate daily aspirin regimens under the widespread assumption that it acts as an infallible shield against cardiovascular disease.
Decades of rigorous clinical research have established that for individuals who have already experienced a cardiovascular event—such as a myocardial infarction, ischemic stroke, or surgical interventions like coronary artery bypass grafting or stent placement—daily low-dose aspirin therapy ("secondary prevention") is undeniably lifesaving, significantly reducing the probability of subsequent vascular events.
However, the clinical consensus for "primary prevention"—protecting individuals who have no history of cardiovascular disease—underwent a dramatic transformation in 2019. The American College of Cardiology and the American Heart Association jointly released updated guidelines explicitly recommending against the routine use of aspirin for primary prevention in adults aged 70 and older. The U.S. Preventive Services Task Force adopted an even more conservative stance, advising against initiating primary prevention aspirin therapy for adults aged 60 and older.
Large-scale randomized clinical trials demonstrated that the cardiovascular benefits of prophylactic aspirin for primary prevention are marginal at best, while the physical risks—most notably major gastrointestinal bleeding—escalate substantially. Dr. Timothy Anderson, an internal medicine physician at the University of Pittsburgh and co-director of the university’s Prescribing Wisely Lab, notes that as human physiology ages, mucosal defenses weaken and vascular fragility increases, driving up hemorrhage risks. In rarer but far more catastrophic instances, aspirin can provoke intracranial bleeding.
Recent data published in JAMA by Anderson and his colleagues demonstrates that public health messaging is gradually penetrating public consciousness; reported aspirin usage for primary prevention within the National Health and Nutrition Examination Survey dropped substantially between 2011 and 2023. Nevertheless, more than a third of adults aged 70 and older reported continuing the daily habit.
Experts emphasize critical nuances within these guidelines. A carefully selected subset of older adults harboring exceptionally high cardiovascular risk profiles may still derive a net benefit from primary prevention aspirin. Conversely, emerging clinical evidence introduces a perplexing paradox: older patients who are already habituated to daily aspirin face an elevated risk of subsequent cardiovascular events if they discontinue the medication abruptly without medical oversight.
Anderson stresses that navigating this transition requires an active, nuanced conversation with a primary care physician to reassess whether the regimen remains appropriate as physiological needs evolve. While older patients often initiate aspirin intake independently out of a commendable desire to proactively manage their health and longevity, modern medicine now offers vastly superior, targeted pharmacological strategies—such as advanced antihypertensive therapies and high-efficacy statin medications—to manage vascular risk without exposing aging bodies to unnecessary hemorrhagic complications.
